An experimental drug combined with chemotherapy caused substantial tumour shrinkage in patients whose pancreatic cancer had spread to other parts of the body, according to new results from a phase I/II clinical trial presented in Barcelona on Friday.

Presenting the RMC-GI-102 trial at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, principal investigator Dr Wungki Park said the combination not only shrank tumours but also showed encouraging prolonged disease control in patients who had not previously received treatment for metastatic disease.

"Pancreatic cancer remains one of the most challenging cancers to treat, particularly because more than half of patients present with disease that has already spread to other organs," said Dr Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York. "We need effective treatments that can achieve deep responses and prolong disease control to curb this aggressively devastating disease."

Most patients with metastatic pancreatic cancer treated with standard chemotherapy survive for between eight and eleven months, and only three per cent are alive five years after diagnosis. Tumour shrinkage is seen in only 23% to 42% of patients on chemotherapy, and most tumours start to grow again after five to six months.

As of September 28, 2026, 61 patients had received the drug combination, with a median follow-up of 18.3 months. Tumours shrank or disappeared in 60.7% of patients, including complete responses in 8.2% in whom tumours were no longer detectable, and tumours stopped growing in 90.2% of patients. The median time before tumours returned or started growing again was 12.8 months.

"What is particularly encouraging about these new and updated results is that we are beginning to see not only a higher percentage of tumour response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival," Dr Park said. "This represents a potentially transformative advance in first-line treatment for patients with metastatic pancreatic cancer, already outpacing the high end for the historical overall survival of 8.5 to 11.1 months with conventional chemotherapy."

More than 90% of pancreatic cancers carry a mutation in the RAS gene that drives the cancer's growth. RAS acts like a molecular switch that tells cells when to grow; in pancreatic cancer the switch becomes stuck in the "on" state, continuously signalling cells to divide. Daraxonrasib is designed to stop the active protein, called RAS (ON), and interfere with the signals cancer cells depend on for survival.

Patients in the trial received 200 mg of daraxonrasib orally once a day, plus two chemotherapy drugs, gemcitabine and nab-paclitaxel, given by intravenous injection on days 1 and 15 of each treatment cycle.

"By combining daraxonrasib with chemotherapy, we are seeing remarkably deep tumour responses in a substantial proportion of patients, together with durable disease control, with a median progression-free survival exceeding one year," Dr Park said. The 12-month overall survival rate was 76.6%.

The most common side effects included rash, diarrhoea, fatigue and chemotherapy-related reductions in blood cells, which were managed with standard medical interventions. Treatment was discontinued because of daraxonrasib-related side effects in five per cent of patients.

Dr Park stressed that the study was early-phase and that patients were not compared with a group receiving chemotherapy alone, so the results must be interpreted carefully. The next step is the global Phase III RASolute-303 trial, which is evaluating daraxonrasib both on its own and in combination with gemcitabine and nab-paclitaxel, compared with chemotherapy alone. Dr Park is the principal investigator of that trial.

Professor Elena Garralda, chair of the symposium and co-director of the Vall d'Hebron Institute of Oncology's clinical research programme in Barcelona, who was not involved in the study, called the results exciting, saying they showed RAS-targeted therapies could be combined with existing treatments from the start to achieve potentially more durable benefits, enabling treatment at an earlier stage of advanced disease.

RAS mutations also drive certain lung, bowel, biliary tract, appendiceal and gynaecological cancers, and separate trials would be needed to test the combination in those diseases. The study was sponsored by Revolution Medicines, the drug's developer.